礼来公司的口服GLP-1受体激动剂Foundayo(奥格列酮)在三项关键的2型糖尿病试验中均展现出更优的糖化血红蛋白A1C控制和体重减轻效果。
印第安纳波利斯,2026年6月8日/PRNewswire/ -- Zepbound(替拉帕肽)的生产商礼来公司(纽约证券交易所代码:LLY)今日公布了ACHIEVE项目中三项3期临床试验的详细…
该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
文章相關商品
系統已根據文章標題、摘要和正文,自動匹配目前在售的強相關藥品。
常見問題
Which products are related to this article?
The system matched these relevant products from the article content: Rybelsus semaglutide 司美格魯肽 索馬魯肽片劑 7mg100錠 線上購買、盧修斯 塞瑞替尼 Ceritinib 線上購買、盧修斯 曲格列汀 Trelagliptin 線上購買、盧修斯 阿普昔騰坦 Aprocitentan 線上購買.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.